Merck’s Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ASCO Annual Meeting
Please read the attached press release for more information Read More
MPA Free Community Forum – Toowoomba, Queensland
Melanoma Patients Australia and Cancer Council Queensland are pleased to host a free Melanoma Community Forum for residents of the Toowoomba region. Public Melanoma Forum Toowoomba • Saturday 31 May…
Read More Novel Immunotherapeutic Safe and Effective in Early-Phase Melanoma Study
A novel immunotherapeutic known as IMCgp100 induced clinical responses with manageable toxicity in patients with advanced melanoma, according to results from a phase I clinical trial presented at the 2014 AACR Annual Meeting.
T-VEC superior to GM-CSF for unresected, metastatic melanoma
Secondary endpoint results from a multicenter, randomized phase 3 trial showed talimogene laherparepvec conferred greater benefit than granulocyte-macrophage colony-stimulating factor for patients with unresected stage IIIB/IIIC or stage IV melanoma, according to study results presented at the HemOnc Today Melanoma and Cutaneous Malignancies meeting in New York.